vancomycin

Summary

Summary: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

Top Publications

  1. pmc The rise of the Enterococcus: beyond vancomycin resistance
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, Center for the Study of Emerging and Re Emerging Pathogens, Houston, Texas 77030, USA
    Nat Rev Microbiol 10:266-78. 2012
  2. ncbi Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
    Catherine Liu
    Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California94102, USA
    Clin Infect Dis 52:e18-55. 2011
  3. pmc Antimicrobial resistance: the example of Staphylococcus aureus
    Franklin D Lowy
    Departments of Medicine and Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 111:1265-73. 2003
  4. ncbi Fidaxomicin versus vancomycin for Clostridium difficile infection
    Thomas J Louie
    University of Calgary, Calgary, AB, Canada
    N Engl J Med 364:422-31. 2011
  5. ncbi Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary
    Catherine Liu
    Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California 94102, USA
    Clin Infect Dis 52:285-92. 2011
  6. pmc Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
    Benjamin P Howden
    Department of Infectious Diseases, Austin Health, Victoria, Australia
    Clin Microbiol Rev 23:99-139. 2010
  7. ncbi Vancomycin resistance in gram-positive cocci
    Patrice Courvalin
    Unite des Agents Antibacteriens, Institut Pasteur, Paris, France
    Clin Infect Dis 42:S25-34. 2006
  8. ncbi Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse
    C H F Hansen
    Section of Biomedicine, Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 57, 1870, Frederiksberg C, Denmark
    Diabetologia 55:2285-94. 2012
  9. ncbi Short-term benefit from oral vancomycin treatment of regressive-onset autism
    R H Sandler
    Section of Pediatric Gastroenterology and Nutrition, Rush Children s Hospital, Rush Medical College, Chicago, IL 60612, USA
    J Child Neurol 15:429-35. 2000
  10. ncbi The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis
    S J van Hal
    Department of Microbiology and Infectious Diseases, Sydney South West Pathology Services Liverpool, South Western Sydney Local Health Network, New South Wales, Sydney, Australia
    Clin Infect Dis 54:755-71. 2012

Detail Information

Publications331 found, 100 shown here

  1. pmc The rise of the Enterococcus: beyond vancomycin resistance
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, Center for the Study of Emerging and Re Emerging Pathogens, Houston, Texas 77030, USA
    Nat Rev Microbiol 10:266-78. 2012
    ..The effects of antibiotics on the gut microbiota and on colonization with vancomycin-resistant enterococci are highlighted, including how enterococci benefit from the antibiotic-mediated ..
  2. ncbi Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
    Catherine Liu
    Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California94102, USA
    Clin Infect Dis 52:e18-55. 2011
    ..Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, ..
  3. pmc Antimicrobial resistance: the example of Staphylococcus aureus
    Franklin D Lowy
    Departments of Medicine and Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 111:1265-73. 2003
  4. ncbi Fidaxomicin versus vancomycin for Clostridium difficile infection
    Thomas J Louie
    University of Calgary, Calgary, AB, Canada
    N Engl J Med 364:422-31. 2011
    ..Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high...
  5. ncbi Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary
    Catherine Liu
    Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California 94102, USA
    Clin Infect Dis 52:285-92. 2011
    ..Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, ..
  6. pmc Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications
    Benjamin P Howden
    Department of Infectious Diseases, Austin Health, Victoria, Australia
    Clin Microbiol Rev 23:99-139. 2010
    The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these ..
  7. ncbi Vancomycin resistance in gram-positive cocci
    Patrice Courvalin
    Unite des Agents Antibacteriens, Institut Pasteur, Paris, France
    Clin Infect Dis 42:S25-34. 2006
    The first vancomycin-resistant clinical isolates of Enterococcus species were reported in Europe in 1988. Similar strains were later detected in hospitals on the East Coast of the United States...
  8. ncbi Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse
    C H F Hansen
    Section of Biomedicine, Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 57, 1870, Frederiksberg C, Denmark
    Diabetologia 55:2285-94. 2012
    ..The aim of this study was to investigate, both during infancy and adulthood, whether treatment with vancomycin, a glycopeptide antibiotic specifically directed against Gram-positive bacteria, could influence immune ..
  9. ncbi Short-term benefit from oral vancomycin treatment of regressive-onset autism
    R H Sandler
    Section of Pediatric Gastroenterology and Nutrition, Rush Children s Hospital, Rush Medical College, Chicago, IL 60612, USA
    J Child Neurol 15:429-35. 2000
    ....
  10. ncbi The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis
    S J van Hal
    Department of Microbiology and Infectious Diseases, Sydney South West Pathology Services Liverpool, South Western Sydney Local Health Network, New South Wales, Sydney, Australia
    Clin Infect Dis 54:755-71. 2012
    Emerging data suggest that vancomycin may be less effective against serious methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibitory concentration (MIC) values at the higher end of the susceptibility range...
  11. ncbi A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity
    Fred A Zar
    University of Illinois at Chicago, Chicago, IL 60612 7323, USA
    Clin Infect Dis 45:302-7. 2007
    ..Metronidazole is still commonly used as first-line treatment for CDAD but has never been compared with vancomycin in a prospective, randomized, double-blind, placebo-controlled trial...
  12. ncbi A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
    Gerald W Tannock
    Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand
    Microbiology 156:3354-9. 2010
    ..Current therapies rely on the administration of metronidazole or vancomycin, which reduce vegetative populations of C. difficile in the bowel...
  13. ncbi Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
    Oliver A Cornely
    University Hospital Cologne, Cologne, Germany
    Lancet Infect Dis 12:281-9. 2012
    ..We aimed to compare efficacy and safety of fidaxomicin and vancomycin to treat patients with C difficile infection in Europe, Canada, and the USA.
  14. pmc Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin
    George Sakoulas
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 46:1492-502. 2002
    ..a nonsense mutation in agrA that was not present in a pulsed-field gel electrophoresis-indistinguishable vancomycin-susceptible isolate from the same patient...
  15. ncbi Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit
    Jose A Martinez
    Division of Geographic Medicine and Infectious Disease and Clinical Care Research, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Arch Intern Med 163:1905-12. 2003
    ..to another case, exposure to a nurse who cares for another case, enteral feeding, and the use of sucralfate, vancomycin hydrochloride, cephalosporins, or antibiotics are among the defined risk factors for acquisition of vancomycin-..
  16. pmc Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300
    Susana Gardete
    Laboratory of Microbiology, The Rockefeller University, New York, New York, USA
    PLoS Pathog 8:e1002505. 2012
    An isolate of the methicillin-resistant Staphylococcus aureus (MRSA) clone USA300 with reduced susceptibility to vancomycin (SG-R) (i.e, vancomycin-intermediate S...
  17. pmc Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy
    K Sieradzki
    The Rockefeller University, New York, New York 10021, USA
    J Clin Microbiol 41:1687-93. 2003
    ..over a period of several weeks from blood samples and from the heart valve of a patient who underwent extensive vancomycin chemotherapy for persistent S. aureus bacteremia...
  18. pmc D-Ala-d-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium
    Francois Lebreton
    Interactions Hôte et Microorganismes des Epithéliums, EA2128, CHU Cote de Nacre, 14033 Caen Cedex, France
    Antimicrob Agents Chemother 55:4606-12. 2011
    Enterococcus faecium UCN71, isolated from a blood culture, was resistant to low levels of vancomycin (MIC, 16 μg/ml) but susceptible to teicoplanin (MIC, 0.5 μg/ml)...
  19. pmc Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States
    Jessica R Galloway-Peña
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
    J Infect Dis 200:1566-73. 2009
    ..The Enterococcus faecium genogroup, referred to as clonal complex 17 (CC17), seems to possess multiple determinants that increase its ability to survive and cause disease in nosocomial environments...
  20. ncbi Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene
    Soju Chang
    Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta 30333, USA
    N Engl J Med 348:1342-7. 2003
  21. pmc OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection
    Thomas J Louie
    Department of Medicine, Division of Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    Antimicrob Agents Chemother 53:261-3. 2009
    During a 10-day treatment for Clostridium difficile infection, OPT-80 and vancomycin were comparably effective in reducing C. difficile counts...
  22. pmc Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus
    Michael Meehl
    Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, NH 03755, USA
    Antimicrob Agents Chemother 51:2679-89. 2007
    ..infections caused by methicillin-resistant Staphylococcus aureus relies heavily upon the glycopeptide antibiotic vancomycin. Unfortunately, this practice has led to an intermediate resistance phenotype that is particularly difficult to ..
  23. ncbi Pneumonia caused by methicillin-resistant Staphylococcus aureus
    Ethan Rubinstein
    University of Manitoba, Winnipeg, Canada
    Clin Infect Dis 46:S378-85. 2008
    ..Rapid institution of appropriate antibiotic therapy, including linezolid as an alternative to vancomycin, is crucial...
  24. pmc Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits
    Katharina Brandl
    Infectious Diseases Service, Department of Medicine, Immunology Program, Sloan Kettering Institute, New York, New York, USA
    Nature 455:804-7. 2008
    Infection with antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a dangerous and costly complication of broad-spectrum antibiotic therapy...
  25. pmc An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
    ..a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype...
  26. ncbi Vancomycin covalently bonded to titanium alloy prevents bacterial colonization
    Valentin Antoci
    Department of Orthopaedic Surgery, Thomas Jefferson University, 1015 Walnut Street, Suite 501, Philadelphia, Pennsylvania 19107, USA
    J Orthop Res 25:858-66. 2007
    ..To test this hypothesis, a Ti rod was covalently derivatized with vancomycin. Reaction efficiencies were evaluated by colorimetric and spectrophotometric measurements...
  27. pmc Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance
    Hui min Neoh
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 52:45-53. 2008
    ..genetic alteration is required for methicillin-resistant Staphylococcus aureus (MRSA) to achieve the level of vancomycin resistance of vancomycin-intermediate S. aureus (VISA)...
  28. ncbi Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia
    Alex Soriano
    Department of Infectious Diseases, Hospital Clinic of Barcelona, Barcelona, Spain
    Clin Infect Dis 46:193-200. 2008
    b>Vancomycin treatment failure in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is not uncommon, even when MRSA is susceptible to vancomycin...
  29. ncbi Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic
    E Breukink
    Center of Biomembranes and Lipid Enzymology, Department of Biochemistry of Membranes, Institute for Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, Netherlands
    Science 286:2361-4. 1999
    Resistance to antibiotics is increasing in some groups of clinically important pathogens. For instance, high vancomycin resistance has emerged in enterococci...
  30. ncbi Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection
    Jane Freeman
    Department of Microbiology, University of Leeds and The General Infirmary, Old Medical School, Leeds, LS1 3EX, UK
    J Antimicrob Chemother 56:717-25. 2005
    Treatment of Clostridium difficile infection (CDI) is limited primarily to either metronidazole or vancomycin. We compared vancomycin and a novel glycolipodepsipeptide, ramoplanin, in both hamster and in vitro gut models of clindamycin-..
  31. pmc Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery
    K W Garey
    University of Houston, College of Pharmacy, Texas Medical Center, 1441 Moursund Street, Houston, TX 77030, USA
    Antimicrob Agents Chemother 52:446-51. 2008
    ..incidence of methicillin-resistant Staphylococcus epidermidis have required that certain institutions choose vancomycin for surgical prophylaxis...
  32. pmc Ability of Candida albicans mutants to induce Staphylococcus aureus vancomycin resistance during polymicrobial biofilm formation
    Melphine M Harriott
    Department of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Antimicrob Agents Chemother 54:3746-55. 2010
    ..More importantly, S. aureus is highly resistant to vancomycin during polymicrobial biofilm formation, with no decreases in bacterial viability observed with up to 1,600 ..
  33. ncbi Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic
    Yinka K Davies
    Department of Pediatrics, Lucile Packard Children s Hospital, Stanford University, Palo Alto, CA 94304, USA
    J Pediatr Gastroenterol Nutr 47:61-7. 2008
    ....
  34. pmc Enhancement of vancomycin activity against biofilms by using ultrasound-targeted microbubble destruction
    Nianan He
    Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    Antimicrob Agents Chemother 55:5331-7. 2011
    ..this study was to investigate whether ultrasound (US)-targeted microbubble (MB) destruction (UTMD) could enhance vancomycin activity against Staphylococcus epidermidis RP62A biofilms...
  35. pmc Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China
    Wenjia Sun
    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, People s Republic of China
    Antimicrob Agents Chemother 53:3642-9. 2009
    The prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) among 1,012 vancomycin-susceptible methicillin (meticillin)-resistant S...
  36. ncbi Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures
    Mary K Hayden
    Dept of Medicine and Pathology, Rush University Medical Center, Chicago, IL 60612, USA
    Clin Infect Dis 42:1552-60. 2006
    ..Using vancomycin-resistant enterococci (VRE) as a marker organism, we investigated the effects of improved environmental cleaning ..
  37. ncbi Sustainable release of vancomycin, gentamicin and lidocaine from novel electrospun sandwich-structured PLGA/collagen nanofibrous membranes
    Dave W Chen
    Department of Mechanical Engineering, Chang Gung University, Tao Yuan, Taiwan
    Int J Pharm 430:335-41. 2012
    This study investigated the in vitro release of vancomycin, gentamicin, and lidocaine from novel electrospun sandwich-structured polylactide-polyglycolide (PLGA)/collagen nanofibrous membranes...
  38. pmc Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization
    Hee Kyoung Choi
    Department of Internal Medicine, Division of Infections Disease, Medical Research Institute, Pusan National University School of Medicine, Busan, Korea
    J Korean Med Sci 26:859-64. 2011
    ..1% (11/84) of the cases and in-hospital mortality rate was 7.1% (6/84). Stool colonization with vancomycin-resistant enterococci (VRE) (P = 0.006), exposure to more than 3 antibiotics (P = 0...
  39. pmc Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis
    Jennifer L Nelson
    Department of Veterinary and Biomedical Sciences, University of Nebraska, 155 VBS, East Campus Loop, Lincoln, NE 68583 0905, USA
    Antimicrob Agents Chemother 51:616-22. 2007
    The most common mechanism by which Staphylococcus aureus gains resistance to vancomycin is by adapting its physiology and metabolism to permit growth in the presence of vancomycin...
  40. ncbi Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:143-9. 2007
    ..Daptomycin, vancomycin and teicoplanin minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were ..
  41. pmc Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens
    Ethan Rubinstein
    Section of Infectious Diseases Department of Internal Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Infect Dis 52:31-40. 2011
    ..Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens...
  42. ncbi Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada
    Jacques Pepin
    Department of Microbiology and Infectious Diseases, University of Sherbrooke, Sherbrooke, Quebec, Canada
    Clin Infect Dis 40:1591-7. 2005
    ..Clinicians who treat patients with Clostridium difficile-associated diarrhea (CDAD) in Quebec, Canada, have noted an apparent increase in the proportion of patients who experience relapse...
  43. pmc Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, 113 8421, Japan
    Antimicrob Agents Chemother 50:428-38. 2006
    ..public health threat and is becoming increasingly resistant to currently available antibiotics, including vancomycin, the drug of last resort for gram-positive bacterial infections. S...
  44. ncbi High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci
    Erika M C D'Agata
    Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN, USA
    Clin Infect Dis 34:167-72. 2002
    The diagnostic accuracy of the rectal swab (RS) culture method in identifying gastrointestinal colonization with vancomycin-resistant enterococci (VRE) is not known...
  45. ncbi Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus
    Linda M Weigel
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Science 302:1569-71. 2003
    b>Vancomycin is usually reserved for treatment of serious infections, including those caused by multidrug-resistant Staphylococcus aureus. A clinical isolate of S...
  46. ncbi Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus
    Satish K Pillai
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Infect Dis 49:1169-74. 2009
    Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains...
  47. ncbi Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
    Michael J Rybak
    Anti Infective Research Laboratory, Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Wayne State University, Detroit Receiving Hospital and University Health Center, Detroit, Michigan 48201, USA
    Clin Infect Dis 49:325-7. 2009
    Practice guidelines for therapeutic monitoring of vancomycin treatment for Staphylococcus aureus infection in adult patients were reviewed by an expert panel of the Infectious Diseases Society of America, the American Society of Health-..
  48. ncbi Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus
    Jeffrey C Hageman
    Centers for Disease Control and Prevention, Atlanta, GA 30033, USA
    Diagn Microbiol Infect Dis 62:440-2. 2008
    A vancomycin-intermediate Staphylococcus aureus (VISA) isolated from the blood of a 46-year-old patient with endocarditis was determined to be pulsed-field type USA300, daptomycin nonsusceptible, and positive for the Panton-Valentine ..
  49. pmc In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model
    Celine Vidaillac
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA
    Antimicrob Agents Chemother 53:4712-7. 2009
    ..model, we evaluated the activity of ceftaroline at 600 mg every 8 h (q8h) and q12h in comparison with that of vancomycin at 1,000 mg q12h over a 72-h time period against six clinical MRSA isolates, including two heterogeneous ..
  50. pmc Imaging peptidoglycan biosynthesis in Bacillus subtilis with fluorescent antibiotics
    Kittichoat Tiyanont
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:11033-8. 2006
    ..the staining patterns observed in Bacillus subtilis using fluorescent derivatives of two PG-binding antibiotics, vancomycin and ramoplanin...
  51. ncbi Global transcriptional response to vancomycin in Mycobacterium tuberculosis
    Roberta Provvedi
    Department of Biology, University of Padua, 35100 Padua, Italy
    Microbiology 155:1093-102. 2009
    ..Mycobacterium tuberculosis transcriptional profile in response to inhibitory and subinhibitory concentrations of vancomycin. Our analysis identified 153 genes differentially regulated after exposing bacteria to a concentration of the ..
  52. ncbi A mouse model of Clostridium difficile-associated disease
    Xinhua Chen
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 135:1984-92. 2008
    ..The aim of this study was to establish a mouse model of antibiotic-induced C. difficile-associated disease (CDAD) that more closely resembles human disease...
  53. ncbi Vancomycin-resistant enterococci: why are they here, and where do they come from?
    M J Bonten
    Department of Internal Medicine and the Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation, University Medical Center Utrecht, The Netherlands
    Lancet Infect Dis 1:314-25. 2001
    ..b>Vancomycin use has been much higher in the USA, where emergence of ampicillin-resistant enterococci preceded emergence of ..
  54. pmc Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
    We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA)...
  55. pmc Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing
    Michael M Mwangi
    Physics Department, Cornell University, Ithaca, NY 14850, USA
    Proc Natl Acad Sci U S A 104:9451-6. 2007
    ..aureus isolates recovered periodically from the bloodstream of a patient undergoing chemotherapy with vancomycin and other antibiotics. After extensive therapy, the bacterium developed resistance, and treatment failed...
  56. pmc Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 48:4665-72. 2004
    ..and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) on the activities of nafcillin, linezolid, vancomycin, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model with simulated ..
  57. pmc Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
    Wafa N Al-Nassir
    Department of Infectious Diseases, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, 10000 Euclid Avenue, Cleveland, Ohio, USA
    Antimicrob Agents Chemother 52:2403-6. 2008
    ..disease (CDAD), oral metronidazole has been recommended as the preferred agent, in part due to concern that vancomycin may be more likely to promote colonization by vancomycin-resistant enterococci (VRE)...
  58. pmc Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia
    George Sakoulas
    Crystal Run Healthcare, 155 Crystal Run Rd, Middletown, NY 10941, USA
    J Clin Microbiol 42:2398-402. 2004
    ..properties of bloodstream isolates of methicillin-resistant Staphylococcus aureus (MRSA) and the efficacy of vancomycin in the treatment of bacteremia...
  59. pmc Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, Tokyo, Japan
    Antimicrob Agents Chemother 53:1231-4. 2009
    We describe here the genetic analysis of a vancomycin-susceptible Staphylococcus aureus (VSSA) strain, Mu50Omega, a strain related to vancomycin-intermediate S. aureus (VISA) strain Mu50...
  60. ncbi Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients
    Thomas P Lodise
    Dept of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY 12208, USA
    Clin Infect Dis 49:507-14. 2009
    Data suggest that higher doses of vancomycin can increase the risk of nephrotoxicity...
  61. pmc Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection
    Anton Y Peleg
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Infect Dis 199:532-6. 2009
    ..By use of clinical and laboratory strains that had been exposed to vancomycin, we showed that both agr functional status and vancomycin minimum inhibitory concentration are determinants ..
  62. pmc Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus
    K Sieradzki
    The Rockefeller University, New York, New York 10021, USA
    J Bacteriol 185:7103-10. 2003
    ..isolates recovered from a bacteremic patient were shown to acquire gradually increasing levels of resistance to vancomycin during chemotherapy with the drug (K. Sieradzki, T. Leski, L. Borio, J. Dick, and A. Tomasz, J. Clin. Microbiol...
  63. ncbi The pharmacokinetic and pharmacodynamic properties of vancomycin
    Michael J Rybak
    Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
    Clin Infect Dis 42:S35-9. 2006
    b>Vancomycin is one of only a few antibiotics available to treat patients infected with methicillin-resistant Staphylococcus aureus and methicillin-resistant, coagulase-negative Staphylococcus species...
  64. pmc Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin
    Iris Figueroa
    Hines Veterans Affairs Hospital, Hines, IL 60141, USA
    Clin Infect Dis 55:S104-9. 2012
    ..originated from patients who had been entered into two phase 3 randomized clinical trials of fidaxomicin versus vancomycin. Isolates of C...
  65. ncbi Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study
    Elisabet I Nielsen
    Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
    Clin Pharmacokinet 48:253-63. 2009
    ..A secondary aim was to evaluate cystatin C as a marker for gentamicin clearance in this patient population...
  66. ncbi Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes
    Stuart Johnson
    Infectious Disease Section, Loyola University Medical Center, Stritch School of Medicine, Maywood, IL 60153, USA
    J Infect 58:403-10. 2009
    ..e., metronidazole or vancomycin) used for the index episode...
  67. pmc Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR
    Florence Depardieu
    Unite des Agents Antibacteriens, Institut Pasteur, 25, rue du Docteur Roux, 75724 Paris Cedex 15, France
    J Clin Microbiol 42:5857-60. 2004
    ..This specific and sensitive technique allows detection of glycopeptide-resistant strains, in particular methicillin-resistant S. aureus, that may escape phenotype-based automated rapid methods...
  68. ncbi Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres
    Erdal Cevher
    Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, Turkey
    Int J Pharm 317:127-35. 2006
    The biodegradable chitosan microspheres containing vancomycin hydrochloride (VANCO) were prepared by spray drying method with different polymer:drug ratios (1:1, 2:1, 3:1 and 4:1)...
  69. pmc Acquisition and duration of vancomycin-resistant enterococcal carriage in relation to strain type
    E M Mascini
    Department of Hospital Hygiene and Infection Prevention, Eijkman Winkler Centre for Microbiology, Infectious Diseases, and Inflammation, University Medical Center Utrecht, Utrecht, The Netherlands
    J Clin Microbiol 41:5377-83. 2003
    In May 2000, the first outbreak of vancomycin-resistant Enterococcus faecium (VREF) was detected in the University Medical Center Utrecht in the nephrology ward...
  70. ncbi Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices
    Meghan N Jeffres
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, MO, USA
    Chest 130:947-55. 2006
    The goal of this investigation was to determine whether vancomycin pharmacokinetic indexes (eg, serum trough concentrations or area under the concentration curve [AUC] values) were associated with mortality for patients with health-care-..
  71. ncbi Differing risk factors for vancomycin-resistant and vancomycin-sensitive enterococcal bacteraemia
    T Peel
    Department of Infectious Diseases, St Vincent s Hospital, Victoria, Australia
    Clin Microbiol Infect 18:388-94. 2012
    ..There were 440 episodes of enterococcal bacteraemia, 80 of which were caused by vancomycin-resistant Enterococcus (VRE)...
  72. pmc In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus
    Yuhan Chang
    Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    Antimicrob Agents Chemother 55:5480-4. 2011
    ..was to evaluate the antibacterial effects of polymethylmethacrylate (PMMA) bone cements loaded with daptomycin, vancomycin, and teicoplanin against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant ..
  73. ncbi Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies
    D L Boger
    Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Med Res Rev 21:356-81. 2001
    b>Vancomycin, teicoplanin, and ramoplanin are potent glycopeptide antibiotics that act by inhibiting bacterial cell wall biosynthesis...
  74. pmc Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States
    Sandra S Richter
    Department of Clinical Pathology Cleveland Clinic, 9500 Euclid Avenue L40, Cleveland, OH 44195, USA
    J Clin Microbiol 49:4203-7. 2011
    The prevalence of heterogeneous intermediate-level resistance to vancomycin (hVISA) in Staphylococcus aureus was assessed by screening a large collection of recent isolates...
  75. pmc Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci
    Ana Maria Rivera
    Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA
    Mayo Clin Proc 86:1230-43. 2011
    ..b>Vancomycin-resistant enterococci are a major cause of infection in the hospital setting and remain resistant to treatment ..
  76. pmc Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vi
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:2156-62. 2008
    ..45 to 1.3 logs). Overall, administration of daptomycin followed by vancomycin demonstrated the most significant kill against all strains in both models...
  77. pmc Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects
    Stephen A Villano
    ViroPharma Incorporated, Exton, Pennsylvania, USA
    Antimicrob Agents Chemother 56:5224-9. 2012
    ..Group 4 (≥60 years old) received oral vancomycin for 5 days, followed by 14 days of VP20621 or placebo...
  78. pmc Emergence of vancomycin-resistant enterococci in Australia: phenotypic and genotypic characteristics of isolates
    J M Bell
    National Antimicrobial Resistance Surveillance Program, Women s and Children s Hospital, North Adelaide, Australia
    J Clin Microbiol 36:2187-90. 1998
    ..multiplex PCR assays for vanA, vanB, vanC1, and vanC2 or vanC3 in order to examine the genetic basis for vancomycin resistance in Australian isolates of vancomycin-resistant Enterococcus faecium and E. faecalis (VRE)...
  79. pmc Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus
    Cory Hafer
    Division of Infectious Diseases, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York, USA
    Antimicrob Agents Chemother 56:5845-51. 2012
    Infections with vancomycin-intermediate Staphylococcus aureus (VISA) have been associated with vancomycin treatment failures and poor clinical outcomes...
  80. ncbi Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
    Grace S Crowther
    Leeds Institute of Molecular Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK
    J Antimicrob Chemother 68:168-76. 2013
    ..NVB302 is a novel type B lantibiotic under evaluation for the treatment of CDI. We compared the responses to NVB302 and vancomycin when used to treat simulated CDI in an in vitro gut model.
  81. ncbi Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols
    Chun Woong Park
    University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Drug Development Division, Lexington, KY 40536 0596, USA
    Int J Pharm 455:374-92. 2013
    Respirable microparticles/nanoparticles of the antibiotics vancomycin (VCM) and clarithromycin (CLM) were successfully designed and developed by novel organic solution advanced spray drying from methanol solution...
  82. ncbi In vitro bactericidal activity of daptomycin against staphylococci
    Peter C Fuchs
    The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070, USA
    J Antimicrob Chemother 49:467-70. 2002
    MICs and minimum bactericidal concentrations (MBCs) of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin (Q-D) were determined for 108 staphylococcal isolates. All strains were susceptible (MICs) to daptomycin (< or =2...
  83. ncbi Acquisition of VanB-type vancomycin resistance by Bacillus subtilis: the impact on gene expression, cell wall composition and morphology
    Paola Bisicchia
    Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland
    Mol Microbiol 81:157-78. 2011
    The vancomycin resistance operons from Enterococci, Staphylococci and Actinomycetes encode a VanRS two-component signal transduction system (TCS) and a suite of enzymes to modify the peptidoglycan biosynthetic precursor lipid II and to ..
  84. pmc Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin
    Emmanuel Mongodin
    Department of Medicine, Medical College of Virginia at Virginia Commonwealth University and the Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, USA
    J Bacteriol 185:4638-43. 2003
    The transcriptomes of vancomycin intermediate-resistance Staphylococcus aureus (VISA) clinical isolates HIP5827 and Mu50 (MIC = 8 micro g/ml) were compared to those of highly vancomycin-resistant S...
  85. pmc Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin
    T Pelaez
    Microbiology and Infectious Diseases Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Antimicrob Agents Chemother 46:1647-50. 2002
    ..The drugs most commonly used to treat diseases associated with C. difficile are metronidazole and vancomycin. Most clinical laboratories assume that all C...
  86. pmc Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin
    P Cottagnoud
    Department of Internal Medicine, Inselspital Bern, Bern, Switzerland
    Antimicrob Agents Chemother 47:144-7. 2003
    b>Vancomycin and gentamicin act synergistically against penicillin-resistant pneumococci in vitro and in experimental rabbit meningitis. The aim of the present study was to investigate the underlying mechanism of this synergism...
  87. ncbi Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia
    Riad Khatib
    Department of Medicine, St John Hospital and Medical Center, Grosse Pointe Woods, MI, USA
    J Antimicrob Chemother 66:1594-9. 2011
    To assess the relevance of vancomycin-intermediate susceptibility (VISA) and heteroresistance (hVISA) in methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.
  88. ncbi Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse
    Ivan K S Yap
    Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London SW7 2AZ, United Kingdom
    J Proteome Res 7:3718-28. 2008
    The effects of the antibiotic vancomycin (2 x 100 mg/kg/day) on the gut microbiota of female mice (outbred NMRI strain) were studied, in order to assess the relative contribution of the gut microbiome to host metabolism...
  89. ncbi Duration of colonization with vancomycin-resistant Enterococcus
    Karin E Byers
    University of Virginia Health System, Charlottesville 22908, USA
    Infect Control Hosp Epidemiol 23:207-11. 2002
    To determine the duration of colonization with vancomycin-resistant Enterococcus (VRE) and the adequacy of 3 consecutive negative cultures to determine clearance.
  90. ncbi Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus
    Shigeru Fujimura
    Research Division for Development of Anti infection Agents, Institute of Development Aging and Cancer, Tohoku University, Sendai, Japan
    J Orthop Sci 14:658-61. 2009
    ..In a previous in vitro study, we showed that treatment with CAM and vancomycin (VCM) eradicated staphylococcal biofilms from surgical implants...
  91. pmc In vitro endothelial cell damage is positively correlated with enhanced virulence and poor vancomycin responsiveness in experimental endocarditis due to methicillin-resistant Staphylococcus aureus
    Kati Seidl
    Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA, USA
    Cell Microbiol 13:1530-41. 2011
    ..Ten methicillin-resistant S. aureus (MRSA) clinical isolates previously tested for their virulence and vancomycin responsiveness in an experimental IE model were assessed in vitro for their haemolytic activity, protease ..
  92. ncbi Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections
    Asad E Patanwala
    The University of Arizona College of Pharmacy, Tucson, AZ, USA
    Curr Med Res Opin 23:185-93. 2007
    This decision-analytic study was intended to determine the expected cost-effectiveness of linezolid compared to vancomycin for treating surgical site infections (SSIs) caused by methicillin-resistant Staphyloccocus aureus (MRSA) from the ..
  93. ncbi Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
    K Hiramatsu
    Department of Bacteriology, Juntendo University, Tokyo, Japan
    Lancet 350:1670-3. 1997
    Since the discovery of the vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50 (minimum inhibitory concentration [MIC] 8 mg/L), there has been concern about the potential spread of such strains throughout Japanese hospitals...
  94. pmc Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
    FARAH BABAKHANI
    Optimer Pharmaceuticals, San Diego, CA, USA
    J Med Microbiol 60:1213-7. 2011
    ..difficile strains, including the hypervirulent restriction endonuclease analysis group BI strains, at concentrations that are many fold below the detected faecal concentrations of these compounds after oral administration of fidaxomicin...
  95. ncbi Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia)
    Biswajit Saha
    Microbiology Laboratory, Department of Physiology, University College of Science, Technology and Agriculture, University of Calcutta, Kolkata, India
    J Med Microbiol 57:72-9. 2008
    A pathogenic vancomycin-resistant Staphylococcus aureus (VRSA) isolate (MIC > or =64 microg ml(-1)) was obtained from a Kolkata hospital in June 2005...
  96. pmc Mouse relapse model of Clostridium difficile infection
    Xingmin Sun
    Tufts Cummings School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA
    Infect Immun 79:2856-64. 2011
    ..Finally, utilizing this model, we demonstrated that vancomycin only delayed disease recurrence, whereas neutralizing polysera against both TcdA and TcdB completely protected ..
  97. pmc Vancomycin-modified implant surface inhibits biofilm formation and supports bone-healing in an infected osteotomy model in sheep: a proof-of-concept study
    Suzanne Stewart
    Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA
    J Bone Joint Surg Am 94:1406-15. 2012
    ..We hypothesized that surface modification of titanium fracture hardware with vancomycin would support bone-healing and prevent bacterial colonization of the implant in a large-animal model.
  98. ncbi Staphylococcus aureus bloodstream infections: definitions and treatment
    G Ralph Corey
    Duke University Medical Center, Durham, North Carolina, USA
    Clin Infect Dis 48:S254-9. 2009
    ..aureus bacteremia and the scientific evidence that forms a basis for the use of these agents for this indication are reviewed...
  99. pmc Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA
    K C Horne
    Infectious Diseases Department, Austin Hospital, Austin Health, P O Box 5555 Studley Rd, Heidelberg, Vic, Australia
    Antimicrob Agents Chemother 53:3447-52. 2009
    Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S...
  100. ncbi Vancomycin-induced leukocytoclastic vasculitis
    Erika Felix-Getzik
    Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts 02115, USA
    Pharmacotherapy 29:846-51. 2009
    b>Vancomycin is well recognized as causing the nonallergic skin reaction known as red man syndrome; however, it is rarely suspected as causative in the setting of an immune-mediated skin reaction...
  101. ncbi Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05
    Gregory Steinkraus
    New Hanover Regional Medical Center, 2131 South 17th Street, Wilmington, NC 28402, USA
    J Antimicrob Chemother 60:788-94. 2007
    To assess whether methicillin-resistant Staphylococcus aureus (MRSA) vancomycin MIC shifts (MIC creep) at a tertiary care institution occurred that may have gone undetected using traditional susceptibility markers (percentage susceptible, ..

Research Grants76

  1. Nanoparticle delivery system for antiturberculosis drug
    Leonid Heifets; Fiscal Year: 2004
    ..pyrazinamide, capreomycin, amikacin, kanamycin, ethionamide, levofloxacin, cycloserine, moxifloxacin, vancomycin, and cefoxitin. These drugs, if efficiently encapsulated, will be tested in a macrophage model of M...
  2. C. Difficile Outcomes and Effectiveness of Treatment Strategies in SCI
    Charlesnika T Evans; Fiscal Year: 2013
    ..will be higher for SCI/D veterans with CDI diagnosis compared to those without such a diagnosis, and 5) oral vancomycin treatment will be associated with lower failure rates and 30-day case fatality than Metronidazole treatments for ..
  3. Vaccine Assembly from Surface Proteins of Staphylococcus Aureus
    Olaf Schneewind; Fiscal Year: 2013
    ..b>Vancomycin and other glycopeptide inhibitors of cell wall synthesis are considered last-resort-therapies for MRSA, however ..
  4. Carbohydrate-based Antiinfective Agents
    Chi Huey Wong; Fiscal Year: 2013
    ..development against dangerous gram-positive strains of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE)...
  5. Structural mechanism of DNA segregation by the pSK41 par system
    Maria Schumacher; Fiscal Year: 2010
    ..aureus, confers resistance to multiple antibiotics, including the drug of last resort, vancomycin. Such multi-drug resistant S. aureus strains are becoming a serious threat to human health...
  6. Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
    THALE CROSS JARVIS; Fiscal Year: 2013
    ..aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), vancomycin resistant enterococcus (VRE), Bacillus anthracis, Listeria monocytogenes and Clostridium difficile...
  7. Evaluation of a new class of antimicrobial agents against Clostridium difficile
    SAUL R contact TZIPORI; Fiscal Year: 2011
    ..b>Vancomycin, the first drug to be used remains the most widely used and the only FDA approved drug, although metronidazole ..
  8. Rapid, Highly Multiplexed and Sensitive Blood Test for Drug-resistant Bacteria
    ARMIN H REITMAIR; Fiscal Year: 2010
    ..faecium, and Shewanella oneidensis as positive control;resistance-specific for methicillin, vancomycin A, and vancomycin B) in purified DNA derived from MSSA, MRSA, VRSA, MSSE, MRSE, VSEfaecalis, vanA VREfaecalis, ..
  9. Defining evolutionary trajectories: Molecular adaptation to antibiotic resistance
    ADIL YOUSIF SHAMOO; Fiscal Year: 2012
    ..of the medical community, methicillin resisistant Staphylococcus aureus (MRSA) were found in over 60% and vancomycin resistant Enterococci (VRE) in nearly 30% of ICU patients compared to 37% and 14% respectively in 1995 and ..
  10. Eukaryotic-type STK/STP-mediated modulation of enterococcal pathogenesis
    Vijay Pancholi; Fiscal Year: 2010
    ..Although information on the complete genome sequence of vancomycin-resistant strain of E...
  11. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
    Taneli Jouhikainen; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, initially in cystic fibrosis (CF) ..
  12. Host defense against Staphylococcus aureus skin infections
    Lloyd S Miller; Fiscal Year: 2010
    ..aureus (MRSA), multi-drug resistant strains, and even strains that are resistant to vancomycin, the last drug to which the organism used to be uniformly sensitive...
  13. PA-50/PA-41 antitoxin antibody therapy for C. difficile infection
    William C Olson; Fiscal Year: 2012
    ..difficile to flourish. Treatment with oral vancomycin or metronidazole leads to symptom resolution in many patients;however, relapse occurs frequently...
  14. Cell wall synthesis enzymes and beta-lactam resistance in Enterococcus faecium
    Louis B Rice; Fiscal Year: 2013
    ..We have also identified and characterized an L,D-transpeptidase (Ldtfm) that is able to confer ?-lactam and vancomycin resistance in the absence of Pbp5, in concert with the activity of a D,D-carboxypeptidase...
  15. Biomarker Screening of Essential Putative Glycoprotease Inhibitor
    Yinduo Ji; Fiscal Year: 2012
    ..aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) is causing increased public health concerns. More than 60% of S...
  16. Preclinical development of a novel antibacterial for Clostridium difficile diseas
    George E Wright; Fiscal Year: 2012
    ..b>Vancomycin and metronidazole are first-line therapy for treatment of CDAD, but there have been reports of treatment failure ..
  17. Multi-specific Antibody Therapy by targeting S. aureus toxins and polysaccharides
    M Javad Aman; Fiscal Year: 2013
    ..aureus strains resistant to methicilin (MRSA) and the last resort antibiotic vancomycin (VISA and VRSA) is posing a major threat to global public health...
  18. Design of New Antimicrobials
    Robert S Hodges; Fiscal Year: 2012
    ..efficacy;at worst, there has been an upsurge of untreatable infections, such as multi-resistant tuberculosis and vancomycin-resistant Enterococcus strains...
  19. Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
    KEMP BAILEY CEASE; Fiscal Year: 2013
    ..problem in each of these venues, and resistance to other antibiotics, including varying degrees of resistance to vancomycin, is increasingly complicating management of S. aureus infections...
  20. Peptidoglycan Biogenesis in Escherichia Coli
    Thomas G Bernhardt; Fiscal Year: 2013
    ..been an effective target for many of our most important antibacterial treatments like penicillin and vancomycin. Penicillin targets the PG synthases called the penicillin binding proteins (PBPs)...
  21. Hemostatic-antibiotic Combination for Prevention of MRSA Surgical Site Infections
    Timothy C Fisher; Fiscal Year: 2010
    ..The objective of this project is to develop a formulation of Ostene that contains vancomycin (Ostene-V)...
  22. Glycopeptide Complexes with Bacterial Cell Walls by REDOR NMR
    Jacob Schaefer; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Vancomycin kills Gram-positive bacteria by interfering with cell-wall biosynthesis. Recently, vancomycin-resistant enterococci and staphylococci have emerged...
  23. A synergy-based therapy against C. difficile
    Kim Lewis; Fiscal Year: 2013
    ..difficile, in contrast to commonly used metronidazole and vancomycin, which were only active against growing bacteria. Upon reaching stationary state, C...
  24. Fecal Bacteriotherapy for Relapsing Clostridium difficile Infection
    COLLEEN RENEE KELLY; Fiscal Year: 2013
    ..While the first relapse is generally treated with a second course of metronidazole or vancomycin, current guidelines recommend a tapering course of oral vancomycin, which is typically given over 4-8 weeks at a ..
  25. Discovering New Anti-Infective Agents from Lysobacter
    Liangcheng Du; Fiscal Year: 2013
    ..with a potent activity against Methicillin-Resistant Staphylococcus aureus (MRSA, ED5014 times more active than vancomycin, a "last resort" antibiotic)...
  26. 3rd ASM Conference on Enterococci
    Don B Clewell; Fiscal Year: 2010
    ..Indeed there is evidence that the recent emergence of high-level vancomycin resistance in Staphylococcus aureus (MRSA) strains is likely a result of acquisition of related determinant(s) ..
  27. Supramolecular Complexes That Mediate Pneumococcal PG Biosynthesis and Virulence
    Malcolm E Winkler; Fiscal Year: 2012
    ..Many clinically relevant antibiotics, including [unreadable]-lactams and vancomycin, target peptidoglycan (PG) biosynthesis...
  28. Targeted Infection Prevention (TIP) Program in Nursing Homes
    Lona Mody; Fiscal Year: 2013
    ..by multiple drug resistant organisms (MDROs) including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and multidrug resistant Gram-negative bacilli (R-GNB)...
  29. Systematic Phenotypic Analysis of the Gram-positive Envelope
    Jason M Peters; Fiscal Year: 2013
    ..Finally, many of the most successful antibiotics in widespread use target the envelope (e.g., penicillin and vancomycin), and the efficacy of antibiotics with cytoplasmic targets is often reduced by issues with envelope permeability...
  30. Immunopathogenesis of Non-alcoholic Fatty Liver Disease
    Senad Divanovic; Fiscal Year: 2013
    ..upregulates IL-17 production by intestinal T cells, exacerbates hepatocellular damage in obese mice- whereas vancomycin- mediated depletion of SFB significantly reduces hepatocellular damage in such mice;and (e) compared to WT ..
  31. Novel oxadiazols for the treatment of drug-resistant gram-positive bacteria
    Shahriar Mobashery; Fiscal Year: 2013
    ..b>Vancomycin-resistant enterococci (VRE) accounts for >25% of the enterococci hospital-acquired infections in the US...
  32. A Four-arm Prospective, Multicenter Study to Assess the Clinical Efficacy, Effect
    Daniel J Sexton; Fiscal Year: 2013
    ..MDR) pathogens that persist in the environment such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), Clostridium difficile, and Acinetobacter...
  33. Molecular Mechanisms Of Daptomycin Resistance In Enterococci
    CESAR AUGUSTO ARIAS; Fiscal Year: 2013
    ..Among these bacteria, vancomycin-resistant enterococci (VRE) are one of the most difficult organisms to treat in hospitals across the US...
  34. Social Networks and the Spread of Influenza and other Nosocomial Infections
    Philip M Polgreen; Fiscal Year: 2012
    ..Also, many infectious disease experts are concerned that the spread of H5N1 influenza or strains of vancomycin-resistant S. aureus could be magnified in hospitals...
  35. Biofilms and Enterococcus faecalis Biology
    Gary M Dunny; Fiscal Year: 2013
    ..The biofilm environment is a likely niche for transfer of high-level vancomycin resistance from enterococci to Staphylococcus aureus...
  36. Anti-MRSA activity of a Bacillus pumilus natural isolate
    Michiko M Nakano; Fiscal Year: 2010
    ..Although vancomycin remains the last resort for treating MRSA infections, vancomycin resistant strains have begun to emerge among HA-..
  37. Single Molecule Studies of Class II Lantibiotic Synthetases
    CHRISTOPHER JAMES THIBODEAUX; Fiscal Year: 2012
    ..several dangerous Gram- positive human pathogens such as methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci...
  38. Oral streptococcal-enterococcal peptide-mediated intercellular communication
    M Margaret Vickerman; Fiscal Year: 2012
    ..Derivatives of pAM373 that carry resistance to multiple antibiotics including a vancomycin, are also cAM373-responsive. Plasmid pAM373 is novel in that it also responds to pheromone-like signals from S...
  39. Defining Precursors to VRSA Emergence: Epidemiology of MRSA &VRE Dual Infection
    Emily Toth Martin; Fiscal Year: 2013
    ..applicant): There is a fundamental gap in our understanding of host and organism precursors to the emergence of vancomycin-resistant Staphylococcus aureus (VRSA), a major public health concern...
  40. Defining evolutionary trajectories: Molecular adaptation to antibiotic resistance
    ADIL YOUSIF SHAMOO; Fiscal Year: 2013
    ..Evolutionary Dynamics'(QED) to study daptomycin and tigecycline resistance in clinical isolates of vancomycin-resistant enterococci (VRE) and to tigecycline resistance in Acinetobacter baumannii...
  41. Development of B-Lock an antibiofilm catheter lock product
    Krzysztof Appelt; Fiscal Year: 2010
    ..albicans and C. parapsilosis, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE)...
  42. Obstetric Pharmacology Research Units Network Center at UTMB-Galveston
    Gary D Hankins; Fiscal Year: 2013
    ..Postparturritional infections due to the MRSA are often serious and potentially life- threatening. Vancomycin has been the antibiotic of choice for treatment of infections caused by MRSA;however, the development of ..
  43. Determine the relative virulence and the temporal expression of sarA paralog gen
    Adhar C Manna; Fiscal Year: 2010
    ..The recent emergence of vancomycin and community-associated methicillin resistance S...
  44. Disinfectant-resistant mycobacteria
    Mary Jackson; Fiscal Year: 2013
    ..levels of resistance to a number of drugs including rifampicin, ciprofloxacin, clarithromycin, erythromycin, vancomycin, tetracycline and linezolid...
  45. Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
    Taneli Jouhikainen; Fiscal Year: 2013
    ..Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AeroVanc) for the treatment of respiratory MRSA infection in CF patients...
  46. A Monoclonal Cocktail for CDI
    ANDREW HIATT; Fiscal Year: 2012
    ..Preliminary testing in vivo has demonstrated protection in the hamster model that was superior to vancomycin. We will produce each of our human mAbs against C...
  47. Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
    MARINA N PROTOPOPOVA; Fiscal Year: 2013
    ..The antibiotic armamentarium for treating C. difficile infection (CDI) is limited and inadequate: although vancomycin and metronidazole are effective for initial disease, they are associated with high rates of relapse or re-..
  48. Does ampicillin resistance or clade type determine GI colonization by E. faecium?
    KAVINDRA SINGH; Fiscal Year: 2013
    ..g., >80% of nosocomial Efm are vancomycin resistant (VRE), almost all of which are ampicillin resistant, the traditional drugs of choice)...
  49. Nature inspired treatments for persistent C. difficile infections
    Julian G Hurdle; Fiscal Year: 2013
    ..the killing of toxin-producing stationary phase cells is not shown by currently prescribed antibiotics vancomycin and metronidazole, which only kill actively growing C. difficile...
  50. New mechanism of resistance to oxazolidinone antibiotics in Staphylococcus aureus
    Alexander S Mankin; Fiscal Year: 2010
    ..and may serve as the last line of defense against infections caused by MRSA with decreased susceptibility to vancomycin. So far, only a few linezolid-resistant S. aureus strains have been described worldwide...
  51. Role of Signal Transduction in Resistance to Cell-Wall Antimicrobials in MRSA
    ROBERT S contact DAUM; Fiscal Year: 2010
    ..Moreover, the effectiveness of the glycopeptide antibiotic vancomycin, long regarded as the antibiotic of last resort for MRSA infections, has begun to decrease due to globally ..
  52. Rapid Molecular Testing for Neonatal Antibiotic-Resistant Pathogens
    Anne J Blaschke-Bonkowsky; Fiscal Year: 2012
    ..using whole blood as a model and 3) perform a clinical study to evaluate the potential impact of NeoDIRECT on vancomycin use in the NICU and a survey to evaluate physician attitudes...
  53. Investigation into the antibiotic activity of the lantibiotic haloduracin
    Rebecca A Splain; Fiscal Year: 2013
    ..Thus, they remain potent against pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE)...
  54. Allosteric therapy of the Clostridium difficile toxins
    Tor Savidge; Fiscal Year: 2013
    ..b>Vancomycin and metronidazole remain treatment options for CDI, but neither is fully effective as is evident by the ..
  55. Pharmacokinetic-Pharmacodynamics of Antimicrobials in Resistant Infections
    Jennifer Le; Fiscal Year: 2013
    ..b>Vancomycin and carbapenems are the primary treatment strategy for serious infections caused by these MDR bacteria...
  56. Wall Teichoic Acid Biosynthesis: A New Target for Therapeutic Intervention?
    SUZANNE L WALKER; Fiscal Year: 2010
    ..The emergence of several vancomycin-resistant Staphylococcus aureus strains in recent years is particularly frightening because S...
  57. Polymicrobial dynamics in transfer of vancomycin resistance to MRSA
    Matthew Ramsey; Fiscal Year: 2013
    ..aureus (MRSA) are leading causes of antibiotic resistant infection, treated mainly with vancomycin. Since 2002, VanA-type vancomycin resistance has moved on plasmids from vancomycin resistant enterococci (VRE) ..
  58. Evaluation of C. difficile Severity in Epidemiologic Studies &in Animal Models
    LAURIE R ARCHBALD-PANNONE; Fiscal Year: 2012
    ..Treatment with metronidazole or vancomycin further suppresses normal flora and contributes to the 15-25% relapse rate and prolonged shedding of the ..
  59. Implementation and Effectiveness of a S. aureus Surgical Site Infection Preventio
    Loreen A Herwaldt; Fiscal Year: 2013
    ..aureus, 2) decolonization of carriers, and 3) prophylaxis with cefazolin and vancomycin for methicillin-resistant S. aureus carriers...
  60. Biosynthesis of Antifungal Lipopeptides from Filamentous Fungi
    Yi Tang; Fiscal Year: 2013
    ..peptide synthetases (NRPSs) are among the most important therapeutics known to mankind, including penicillin, vancomycin and cyclosporin...
  61. Effects of the Intestinal Microbiota on Infections During Bone Marrow Transplant
    Ying Taur; Fiscal Year: 2013
    ..HSCT), and determine the relationship between flora and the risk for two infections, bacteremia with vancomycin-resistant Enterococcus (VRE) and Clostridium difficile-associated diarrhea (CDAD)...
  62. Retrocyclins: Cyclic mini-defensins that inactivate anthrax toxins
    ROBERT IRVING contact LEHRER; Fiscal Year: 2010
    ..In vitro, 8-defensins are broad-spectrum viral entry inhibitors, are effective against vancomycin-resistant enterococci (VRE), and appear to be highly promising agents to protect against infections initiated by ..
  63. Harvard-wide Program on Antibiotic Resistance
    Suzanne Walker; Fiscal Year: 2013
    ..This has become urgent with the introduction of vancomycin resistance from VRE (leading causes of multidrug resistant hospital infection)...
  64. HTS assay and configuration for inhibitors of the UDP-Mur formation pathway
    Michael McNeil; Fiscal Year: 2009
    ..is a well established mode of action of effective antibacterial and is primarily accomplished with 2-lactams and vancomycin. However, M...
  65. Subgingival Drug Delivery for Periodontitis Prevention and Treatment
    MARTYN DARBY; Fiscal Year: 2009
    ..Our previous work has identified high-affinity peptides that bind the glycopeptide antibiotic vancomycin, which we hope to build upon by targeting the gram- negative-killing drug minocycline...
  66. Novel antibacterials targeting the 50S ribosomal subunit
    Joyce Sutcliffe; Fiscal Year: 2005
    ..Looking ahead, this agent would cover strains that have resistance to macrolides, quinolones, vancomycin, ¿-lactams, Synercid(r), and Linezolid...
  67. Detection of Antibiotic Resistance Genes in Bacterial Agents of Hospital-Acquired
    Andrew Levin; Fiscal Year: 2009
    ..resistance to [unreadable]-lactams and fluoroquinolones in Gram-negative bacteria, and to methicillin and vancomycin in Gram-positive bacteria...
  68. ORGANIC NANOTUBES DESIGN AND BIOLOGICAL APPLICATIONS
    M Ghadiri; Fiscal Year: 2009
    ..and selective in vitro and in vivo (mice) activities against multidrug-resistant bacterial infections including vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA)...
  69. WHOLE GENOME SHOTGUN SEQUENCING OF STREPTOCOCCUS MITIS
    Herve Tettelin; Fiscal Year: 2001
    ..It is an emerging source of septicemia in cancer patients, and the first vancomycin-resistant S. mitis isolate was reported in one such case. Phylogenetically, S. mitis and the overt pathogen S...
  70. STAPHYLOCOCCAL VANCOMYCIN AND METHICILLIN RESISTANCE
    BRIAN WILKINSON; Fiscal Year: 2001
    ..The glycopeptide antibiotic vancomycin was the sole remaining antibiotic to which S. aureus remained uniformly susceptible...
  71. Proline uptake in staphylococcus aureus pathogenesis
    WILLIAM SCHWAN; Fiscal Year: 2002
    ..Recent outbreaks of community-acquired S. aureus possessing methicillin resistance and the emergence of vancomycin-resistant S. aureus strains mean that some strains may be untreatable by any antibiotic. Because S...
  72. Structure and function of family 1 glycosyltransferases
    R Garavito; Fiscal Year: 2006
    ..of 3 subfamilies of the family 1 NDP-sugar glycosyltransferases (GTFs): GTFs involved in the biosynthesis of vancomycin group antibiotics, GTFs which create sterol glucosides, and two GTFs involved in the glycosylation of ..
  73. CONTRIBUTION OF LPS TO EXP ENTEROCOCCAL SEPSIS
    Christopher Papasian; Fiscal Year: 2000
    ..and have a propensity for rapid development of resistance to broad-spectrum antibacterial agents including vancomycin, aminoglycosides, and extended spectrum beta-lactam antimicrobial agents...
  74. GORDON CONFERENCE ON STAPHYLOCOCCAL DISEASES
    Henry Chambers; Fiscal Year: 1999
    ..aureus autolysins, therapeutics, vancomycin resistance, methicillin resistance, genomics, gene regulation, immunity and vaccine development...
  75. GENOME ANALYSIS OF STAPHYLOCOCCUS EPIDERMIDIS
    Steven Gill; Fiscal Year: 2001
    ..increase in methicillin resistant isolates (MRSE) and clinical isolates with intermediate resistance to vancomycin. Because S...
  76. REGULATIONS OF IRON ACQUISITATION BY S AUREUS
    RADHESHYAM JAYASWAL; Fiscal Year: 2000
    ..The acquisition of broad antibiotic resistance in this bacterium, especially the methicillin and vancomycin-resistant S. aureus strains, poses a major threat to public health...